Search Results - "Rouce, R.H."

Use of highly characterized EBV-Specific T Cells outside of the immediate Post-Transplant setting by Rouce, R.H, Thakkar, A, Sharma, S, Shah, N, Reyna, A, Ramos, C.A, Lapteva, N, Zhang, H, Mehta, B, Perconti, S, McKenna, M, Gee, A.P, Lulla, P.D, Castello, J, Brenner, M, Heslop, H, Rooney, C

“…Background & AimGiven the efficacy of donor-derived EBV-specific T cells (EBVSTs) in the post- HSCT environment, and considering many lymphoma patients are…”
Get full text

Use of highly characterized EBV-specific T cells for treatment of EBV+ lymphoma outside of the HSCT setting by Rouce, R.H, Shah, N, Thakkar, A, Sharma, S, Reyna, A, Zhang, H, Mehta, B, Lulla, P.D, Pingali, S, Lapteva, N, Gee, A, Leen, A, Heslop, H, Rooney, C

Get full text

The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia by Rouce, R H, Shaim, H, Sekine, T, Weber, G, Ballard, B, Ku, S, Barese, C, Murali, V, Wu, M-F, Liu, H, Shpall, E J, Bollard, C M, Rabin, K R, Rezvani, K

“…Natural killer (NK) cells are key components of the innate immune system, providing potent antitumor immunity. Here, we show that the tumor growth factor-β…”
Get full text

Long term follow up of subsequent malignancies in patients treated with genetically modified immune effectors by Muhsen, I.N., Steffin, D., Ahmed, N., Hegde, M., Dakhova, O., Wang, T., Wu, M., Gottschalk, S., Whittle, S., Lulla, P., Mamonkin, M., Omer, B., Rouce, R.H., Heczey, A., Metelitsa, L., Hill, L., Ramos, C.A., Rooney, C., Brenner, M., Heslop, H.

Get full text

87 - Use of highly characterized EBV-specific T cells for treatment of EBV+ lymphoma outside of the HSCT setting by Rouce, R.H., Shah, N., Thakkar, A., Sharma, S., Reyna, A., Zhang, H., Mehta, B., Lulla, P.D., Pingali, S., Lapteva, N., Gee, A., Leen, A., Heslop, H., Rooney, C.

Get full text